ASH 2009 meeting report—Top 10 clinically oriented abstracts in coagulation medicine and platelet disorders

No abstract is available for this paper.

• Publication year

  2010

• Venue

  American Journal of Hematology

• Publication date

  2010-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajh.21632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic polymorphisms in cytochrome P450s, GSTs, NATs, alcohol consumption and risk of non‐Hodgkin lymphoma

  2010cited by this paper
• [The 5q- syndrome].

  2010influential reference
• Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune‐mediated severe ADAMTS13‐deficiency: a report of four cases and a systematic review of the literature

  2009cited by this paper
• Long‐term follow‐up of 386 consecutive patients with essential thrombocythemia: Safety of cytoreductive therapy

  2009cited by this paper
• Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.

  2009cited by this paper
• Mutations of ASXL1 gene in myeloproliferative neoplasms

  2009cited by this paper
• Genetic polymorphisms in glutathione S‐transferases and cytochrome P450s, tobacco smoking, and risk of non‐Hodgkin lymphoma

  2009cited by this paper
• Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

  2009cited by this paper
• Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low‐risk essential thrombocythemia and polycythemia vera

  2009cited by this paper
• Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

  2009cited by this paper
• Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.

  2009cited by this paper
• A phase II study of 5‐day intravenous azacitidine in patients with myelodysplastic syndromes

  2009cited by this paper
• Pomalidomide is active in the treatment of anemia associated with myelofibrosis.

  2009cited by this paper
• Auto-adjusting positive airway pressure in children with sickle cell anemia: results of a phase I randomized controlled trial

  2009cited by this paper
• The systems biology‐based argument for taking a bold step in chemoprophylaxis of sickle vasculopathy

  2009cited by this paper
• Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.

  2009cited by this paper
• Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.

  2009cited by this paper
• Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

  2009cited by this paper
• Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.

  2009cited by this paper
• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

  2009cited by this paper
• Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation

  2009cited by this paper
• A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity.

  2009cited by this paper
• A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M 2 ) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis.

  2009cited by this paper
• TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

  2009cited by this paper
• Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

  2009cited by this paper
• The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

  2009cited by this paper
• The changing classification of myelodysplastic syndromes: what's in a name?

  2009cited by this paper
• GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.

  2009cited by this paper
• Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis.

  2009cited by this paper
• Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

  2009cited by this paper
• A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple

  2009cited by this paper
• Pomalidomide (CC4047) Plus Low Dose Dexamethasone (Pom/dex) Is Active and Well Tolerated in Lenalidomide Refractory Multiple Myeloma (MM).

  2009cited by this paper
• Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.

  2009cited by this paper
• Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

  2009cited by this paper
• Asthma management: Reinventing the wheel in sickle cell disease

  2009cited by this paper
• Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials.

  2009cited by this paper
• Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation

  2009cited by this paper
• Pulmonary hypertension does not affect the autonomic nervous system dysfunction of sickle cell disease

  2009cited by this paper
• A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD.

  2009cited by this paper
• Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1‐PDGFRA fusion transcript: extended follow‐up

  2009cited by this paper
• Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression

  2009cited by this paper
• Repeated courses of rituximab in chronic ITP: Three different regimens

  2009cited by this paper
• Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

  2009cited by this paper
• Karyotype complements the International Prognostic Scoring System for primary myelofibrosis

  2009cited by this paper
• Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.

  2009cited by this paper
• Bendamustine: rebirth of an old drug.

  2009cited by this paper
• Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.

  2009cited by this paper
• High Complete and Very Good Partial Response Rates with Bortezomib—Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial.

  2009cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009cited by this paper
• Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

  2009cited by this paper
• Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

  2009cited by this paper
• Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).

  2009cited by this paper
• Conventional cytogenetics in myelofibrosis: literature review and discussion

  2009cited by this paper
• Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions

  2009cited by this paper
• Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: A report of 13 cases and review of the literature

  2009cited by this paper
• Human T regulatory cell therapy: take a billion or so and call me in the morning.

  2009cited by this paper
• Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years.

  2009cited by this paper
• Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

  2009influential reference
• Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis—increased serum ferritin or transfusion load does not

  2009cited by this paper
• Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

  2009cited by this paper
• Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML

  2009cited by this paper
• Survival in young patients with intermediate‐/high‐risk myelofibrosis: Estimates derived from databases for non transplant patients

  2009cited by this paper
• The cost of health care for children and adults with sickle cell disease

  2009cited by this paper
• Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

  2008cited by this paper
• Cytogenetic features in myelodysplastic syndromes

  2008cited by this paper
• Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: Clinicopathologic correlations and new insights from the prelenalidomide era

  2008influential reference
• Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents

  2008cited by this paper
• JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

  2008cited by this paper
• Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts

  2008cited by this paper
• Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria

  2008cited by this paper
• Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

  2008cited by this paper
• Sickle cell disease and pulmonary hypertension in Africa: A global perspective and review of epidemiology, pathophysiology, and management

  2008cited by this paper
• Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

  2008cited by this paper
• Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

  2008cited by this paper
• Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients

  2008cited by this paper
• Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis

  2008cited by this paper
• Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes

  2008cited by this paper
• Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia

  2008cited by this paper
• Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

  2008cited by this paper
• Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis

  2008cited by this paper
• Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation

  2008cited by this paper
• Cigarette smoking, alcohol drinking, and risk of lymphoid neoplasms: results of a French case–control study

  2008cited by this paper
• Evidence and expertise in the management of polycythemia vera and essential thrombocythemia

  2008cited by this paper
• Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies.

  2008cited by this paper
• The role of the immune system in myelodysplasia: implications for therapy.

  2008cited by this paper
• Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension

  2008cited by this paper
• New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

  2008cited by this paper
• Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma

  2008cited by this paper
• Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.

  2008cited by this paper
• Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

  2008cited by this paper
• Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy

  2008cited by this paper
• Polymorphisms in xenobiotic‐metabolizing genes and the risk of chronic lymphocytic leukemia and non‐Hodgkin's lymphoma in adult Russian patients

  2008cited by this paper
• Pulmonary complications of sickle cell disease.

  2008cited by this paper
• Pulmonary hypertension of sickle cell disease: More than just another lung disease

  2008cited by this paper
• Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

  2008cited by this paper
• Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.

  2008cited by this paper
• Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation.

  2008cited by this paper
• Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency

  2008cited by this paper
• Longitudinal analysis of pulmonary function in adults with sickle cell disease

  2008cited by this paper
• TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

  2008cited by this paper

• ASH 2010 meeting report—Top 10 abstracts in hematopoietic stem cell transplantation

  2011cites this paper
• Primary pulmonary non‐Hodgkin's lymphoma: A retrospective analysis of 29 cases in a Chinese population†

  2010cites this paper
• Informational needs assessment of non‐Hodgkin lymphoma survivors and their physicians

  2010cites this paper
• Preclinical and clinical activity of ATP mimetic JAK2 inhibitors.

  2010cites this paper
• Clinical manifestations of combined factor V and VIII deficiency: A series of 37 cases from a single center in India†

  2010cites this paper
• Hematopoietic stem cell transplantation: ASBMT/CIBMTR 2010 tandem meeting highlights and discussion†

  2010cites this paper
• The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population†

  2010cites this paper
• Pain rate and social circumstances rather than cumulative organ damage determine the quality of life in adults with sickle cell disease†

  2010cites this paper
• A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B‐precursor acute lymphoblastic leukemia cell lines†

  2010cites this paper
• Analysis of the REL, BCL11A, and MYCN proto‐oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia†

  2010cites this paper